Key Takeaways
- Research and Development Advancements: Bee Vectoring Technologies International Inc. (BVT) announced significant R&D progress for its biological control agent, Clonostachys rosea strain CR-7, for soybean seed treatment.
- Safety and Compatibility: Studies confirmed CR-7’s safety and compatibility with other seed treatments, ensuring it does not harm soybean seeds or plants.
- Market Potential: The seed treatment market offers substantial revenue opportunities, with potential annual royalties through future licensing agreements.
- Global Impact: Soybeans, a major global crop, represent a significant market, especially in leading producers like Brazil and the United States.
BVT Advances CR-7 for Soybean Seed Treatment
Bee Vectoring Technologies International Inc. (BVT) has announced significant advancements in the Research and Development (R&D) of its proprietary biological control agent, Clonostachys rosea strain CR-7 (CR-7), for use as a seed treatment for soybeans. This breakthrough emphasizes the product’s safety and compatibility on seeds, paving the way for its commercialization in the agriculture sector.
Investment in Research
“Investing in this research is crucial for understanding the potential market for a CR-7 seed treatment product,” stated Ashish Malik, CEO of BVT. “This study allowed us to assess the effectiveness and safety of CR-7 on soybean seed, duration of action, and compatibility with other treatments. These are fundamental studies to support launching this product and further advancing our partnership opportunities.”
Proven Safety and Compatibility
Dr. Mason Newark, Field Technical Manager at BVT, highlighted the extensive testing over two years which confirmed CR-7’s exceptional safety profile on soybean seeds. “These results establish CR-7 as an excellent candidate for seed treatment, given its long shelf life, compatibility with other common seed treatment products, and its safety for use on seeds,” Dr. Newark said.
Market Potential
The seed treatment market represents a significant new revenue stream for BVT. Through a potential future licensing agreement, BVT could earn substantial annual royalties from this application. CEO Malik emphasized ongoing collaborations with major global multinationals, who seek to enhance their seed treatment offerings in soybeans—a crop valued at $155 billion annually and projected to reach $278 billion by 2031.
Research Highlights
Extended Viability: CR-7 demonstrates a long shelf life once coated on soybean seeds, maintaining its effectiveness even if seeds are planted 6-12 months post-treatment. This ongoing shelf-life study provides BVT’s sales partners with a strong value proposition and a robust product.
Compatibility with Other Seed Treatments: Testing confirms CR-7’s compatibility with other seed treatment products, including biologicals and chemical pesticides, ensuring it integrates seamlessly into existing agricultural practices.
Proven Safety: Extensive safety tests show that CR-7 does not harm soybean plant germination or growth, ensuring plant health from seed through maturity.
Additional Observations
BVT’s R&D team also observed no negative interactions between CR-7 and other microbes. CR-7 showed significant compatibility with major and commonly used fungicides. Notably, CR-7 remains detectable in seedlings up to nine months, indicating its durability and effectiveness. Dr. Newark noted, “Our ongoing R&D efforts continue to showcase the robustness of CR-7, with promising results indicating its effectiveness remains intact for up to nine months and potentially beyond. Now we are testing for 20 months plus viability. What we’ve found so far that’s particularly exciting is that CR-7 grows with the plant and creates a broader zone of protection from the seed stage to well into the roots and stems of the plant.”
Bee Vectoring Technologies Latest News:
Advances Strategic Partnerships in Global Agriculture (2024/03/01)
Bee Vectoring Technologies International Inc. (BVT) is strategically partnering with multinational agriculture companies to expand its market presence. The company’s CEO, Ashish Malik, is optimistic about these initiatives and highlighted the successful trials of its innovative solutions, particularly its plant-beneficial microbe, Clonostachys rosea CR-7. The technology has demonstrated significant value, outperforming base seed treatments and showing effectiveness against Sudden Death Syndrome in soybeans. These partnerships are expected to fuel BVT’s long-term success in the global agriculture sector.
BVT and Agrobío’s Trial (2024/02/16)
Bee Vectoring Technologies International Inc. (BVT) has partnered with Agrobío SL to conduct trials of its innovative natural precision agriculture system. The trial is focused on greenhouse tomato crops in Spain and introduces a groundbreaking approach to pest management, combining the forces of nature with cutting-edge science. The collaboration is part of the EU-funded ADOPT-IPM project aimed at enhancing the EU’s competitiveness and addressing climate change.
Multi-National Trials in Mexico (2024/02/01)
Bee Vectoring Technologies International Inc. (BVT) has initiated demonstration trials in Mexico with a leading multi-national berry producer, utilizing its Vectorite with CR-7 biological fungicide and natural precision agriculture system. This collaboration marks a strategic effort by BVT to showcase the scalability and effectiveness of its technology across various crops and nations, with the trials serving as a paid endorsement by the grower. BVT’s venture into Mexico aligns with its global strategy to provide sustainable agricultural solutions, emphasizing the company’s commitment to enhancing crop protection through environmentally friendly practices.
BVT Partners with MBFi (2024/01/17)
Bee Vectoring Technologies International Inc. (BVT) partners with Microbial Biological Fertilizers International (MBFi) for trials in South Africa, testing BVT’s innovative bee vectoring technology against traditional spray methods. This collaboration, which uses BVT’s patented dispenser and Vectorite powder, aims to offer an eco-friendly alternative to chemical pesticides and quickly enter the South African market using MBFi’s registered biologicals. The extensive trials will cover a wide range of crops, highlighting BVT’s commitment to sustainable agriculture and its potential impact on the global $240 billion crop protection and fertilizer market.
BVT Debt Settlement (2023/12/25)
Bee Vectoring Technologies International Inc. (BVT), an agricultural technology company, has undertaken a significant financial restructuring by settling $1,130,000 in debts through the issuance of 18,833,334 Common shares, each valued at $0.06. This strategic move aims to enhance the company’s financial stability and growth prospects. Alongside this, BVT has issued 6,868,155 restricted share units (RSUs) to its directors, employees, and consultants, with 50% vesting immediately and the remainder within three to four months. This step, part of the company’s compensation restructuring, aligns the interests of its staff with the company’s long-term goals. These shares are subject to a statutory hold period of four months and a day, ensuring regulatory compliance and market stability. This approach signifies BVT’s commitment to managing liabilities effectively while investing in its workforce, reflecting a positive outlook for its future.
Bee Vectoring Negotiates Loan Financing (2023/11/27)
Bee Vectoring Technologies International Inc. has secured up to CAD 1 million in funding through a loan agreement with two capital firms, supporting the company’s growth plans in the agricultural sector. The loan will be provided in tranches of $100,000, with flexible repayment options and an interest rate of 15%. Funds will be used for research, development, marketing initiatives, and working capital needs.
Bee Vectoring Technologies Completes Debt Settlement (2023/11/27)
Bee Vectoring Technologies (BVT) has completed its debt settlement agreement by issuing 2,765,138 common shares at $0.06 per share, valued at $165,908.34. The shares are subject to a statutory hold period that ends on March 25, 2024. BVT is an innovative agriculture technology company that uses natural precision agriculture systems to improve crop protection and yield while protecting soil and environmental health.
BVT Achieves Remarkable Growth (2023/09/14)
Bee Vectoring Technologies International Inc. (CSE: BEE) (OTCQB: BEVVF) is making waves in the agriculture industry with its groundbreaking precision agriculture system that utilizes commercially grown bees to deliver biological pesticide alternatives to crops. The company has recently announced a staggering 196% year-over-year sales growth in the Pacific Northwest blueberry market, accompanied by a high customer retention rate and the addition of new customers. This impressive growth demonstrates the immense potential of BVT’s eco-friendly approach to crop protection and highlights the increasing demand for sustainable farming practices.
BVT & BioSafe: Redefining Sustainable Agriculture (2023/09/29)
Bee Vectoring Technologies International Inc. (BVT) has partnered with BioSafe Systems to distribute its Clonostachys rosea CR-7 microbe in the foliar application market. This marks BVT’s entry into a new market segment and opens up new opportunities for sustainable agriculture. BVT will receive royalties from BioSafe Systems for each sale made. The efficacy of CR-7 as a biofungicide has been affirmed by BVT, paving the way for its use in the foliar business. This aligns with BVT’s strategic vision of discovering innovative applications for CR-7 and geographic expansion. With its precision vectoring technique, BVT aims to replace chemical pesticides and reduce wastage associated with traditional plant protection.
BVT Announces Share Issuance and Corporate Developments (2023/07/05)
Bee Vectoring Technologies International Inc. (BVT), an innovative agriculture technology firm, has announced plans to issue 1,111,370 common shares for $0.06 per share. This issuance is intended to settle a semi-annual interest payment due to Sorbie Bornholm LP following the issuance of 1,900 notes for gross proceeds of $1,900,000 from a private placement that closed on July 11, 2022. The shares will be issued under prospectus exemptions per Canadian securities laws, and there will be no hold periods or resale restrictions. The anticipated closing date for the private placement and share issuance is July 12, 2023.
BVT Expands Into Cranberry Market (2023/06/29)
Bee Vectoring Technologies International Inc. (BVT) has announced its expansion into the cranberry market by signing its first customer. The Wisconsin-based grower will use BVT’s proprietary Vectorite with CR-7 (Clonostachys rosea CR-7) biological fungicide and natural precision agriculture system in their cranberry fields for the upcoming growing season.
Bee Vectoring Technologies conducted a successful trial of its natural precision agriculture system in cranberry crops in 2022, resulting in increased yield and reduced fruit rot. The grower has doubled their BVT order for 2023. BVT has had success in other markets, including blueberries, strawberries, raspberries, and blackberries, and the expansion into cranberries signifies the company’s growing momentum. BVT’s precision vectoring system enables the delivery of biological pesticide alternatives to crops, resulting in enhanced crop protection and yield compared to traditional chemical pesticides.
Bee Vectoring Technologies Secures Order With US Blueberry Grower (2023/05/25)
Bee Vectoring Technologies International Inc. (BVT) has announced a record-setting sales order from one of the largest blueberry growers in the United States. The agreement will see the integration of BVT’s Vectorite with CR-7, a proprietary biological fungicide, into the grower’s operations in the Pacific Northwest for the upcoming season.
Bee Vectoring Technologies Reports On 2nd Year Trial Results (2023/03/08)
Bee Vectoring Technologies International Inc. has reported positive second-year trial results for its proprietary biological control agent Clonostachys rosea strain CR-7 (CR-7) on soybeans. The trials showed that adding CR-7 over the base seed treatment led to higher yields in soybean plants, as measured over 16 replicated plots across four locations. Furthermore, the results showed that CR-7 was equivalent to the chemical standard in effectiveness and even better than the biological standard. Additionally, the plant health, vigor, and biomass measures showed the same positive outcomes as in the first year, indicating the scalability of BVT’s proprietary CR-7 in the soybean seed treatment market.
Bee Vectoring Technologies Enters the CEA Market (2022/10/13)
Bee Vectoring Technologies International Inc. announced its first sales commitment in the Controlled Environment Agriculture market. A leading industry innovator in vertical farming will be conducting a paid pilot of the BVT system as a crop productivity tool. This sector holds significant growth opportunity for BVT given the global CEA market was valued at over US$74 billion in 2021 and is estimated to reach US$125 billion by 2027. The company’s Sales Manager, Ian Collinson, stated that CEA is the future of agriculture and can help indoor growers’ productivity by producing better quality fruits and vegetables. Meanwhile, the Company announced the resignation of Mark Kohler from the board of directors, effective October 7th, 2022.
3 Comments